The Ivy Brain Tumor Center (Phoenix) and University of California, San Francisco will partner on a Phase 0 clinical trial to test GSK’s (NYSE:GSK) Zejula in patients with newly diagnosed glioblastoma and recurrent glioma (grades II–IV). Zejula (niraparib) is a daily oral poly (ADP-ribose) polymerase (PARP) inhibitor. FDA introduced Phase 0 clinical trials in 2004…